Host responses in an ex-vivo human skin model challenged with Malassezia sympodialis

FUNDING: This project was funded by a Wellcome Trust Strategic Award for Medical Mycology and Fungal Immunology (097377/Z/11/Z). We would like to acknowledge the support of Internal Funding through a Core Facilities Voucher from the University of Aberdeen. ACKNOWLEDGMENTS: The authors gratefully acknowledge the Technology hubs at the University of Aberdeen (Microscopy and Histology, qPCR facility and Proteomics) for their support, sample processing and training. Special thanks to Professor Annika Scheynius from the Karolinska Institute, Stockholm, Sweden for sharing her expertise and constructive discussions and for giving us the inspiration to work on Malassezia.Peer reviewedPublisher PD

Higher In vitro Proliferation Rate of Rhizopus oryzae in Blood of Diabetic Individuals in Chronic Glycaemic Control Compared with Non-diabetic Individuals

We thank all members of the Laboratory of Clinical Microbiology in the Hospital General Dr. Manuel Gea González, Instituto Nacional de Rehabilitacion and Hospital General de México. Also, thanks to the Wellcome Trust Strategic Award, corresponding author’s scholarship sponsor. Financial Support This study did not have pharmaceutical or grant support, and resources were obtained from institutional budgets.Peer reviewedPublisher PD

Malassezia sympodialis Mala s 1 allergen is a potential KELCH protein that cross reacts with human skin

Open Access via the OUP Agreement We thank Giuseppe Ianiri and Joe Heitman for their continuous support and many insightful discussions. Thanks to the Microscopy and Histology Facility at the Institute of Medical Sciences, University of Aberdeen, for sample processing and access to microscopes. Thanks to Dr. David Stead and the Aberdeen Proteomics Facility, University of Aberdeen for the proteomics analysis. Funding This project was funded by a Wellcome Trust Strategic Award for Medical Mycology and Fungal Immunology (097377/Z/11/Z). D.E.C.L., C.M,. and D.M. acknowledge funding from the Wellcome Trust Strategic Award for Medical Mycology and Fungal Immunology 097 377/Z/11/Z. A.S. acknowledges, the Swedish Cancer and Allergy Fund.Peer reviewedPublisher PD

Monoclonal Human Antibodies That Recognise the Exposed N and C Terminal Regions of the Often-Overlooked SARS-CoV-2 ORF3a Transmembrane Protein

Acknowledgments: The authors would like to gratefully acknowledge the efforts of Julia Martinez Fraile, Richard Lofthouse, Lewis Penny, Mohammad Arastoo and Natalia Cattelan for providing training and assistance with various experimental procedures described in this study. The authors also thank the University of Aberdeen Microscopy and Histology Facility for training and access to fluorescence microscopy and Aberdeen Proteomics for access to BiacoreX100 for SPR binding analysis. Funding: Chief Scientist Office, Scottish Government (COV/ABN/20/01). MRC Centre for Medical Mycology at the University of Exeter (MR/P501955/2).Peer reviewedPublisher PD

An ex-vivo human skin model to study superficial fungal infections

Funding This project was funded by a Wellcome Trust Strategic Award for Medical Mycology and Fungal Immunology 097377. We would like to acknowledge the support of the Medical Research Council Centre for Medical Mycology at the University of Aberdeen (MR/N006364/1). Acknowledgments Thanks to Ms. Lucinda Wight in the Microscopy and Histology Facility at the Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom for training on the use of microscopes and the SEM processing. Thanks to Dr. David Stead in the Aberdeen Proteomics Facility, University of Aberdeen, Aberdeen, United Kingdom for the processing of protein samples.Peer reviewedPublisher PD

Methods for SARS-CoV-2 hospital disinfection, in vitro observations.

This work was funded by National Health Service Grampian Charity. DECL received support from UK Biotechnology and Biological Sciences Research Council and the USA National Science Foundation (BB/W002760/1). Acknowledgment We thank John Ellison for provision of the je2Care 222nm UVC Lamp, and Novus ltd for access to the EORG water ozonation unit.Peer reviewedPublisher PD

Influenza challenging the diagnosis and management of pulmonary coccidioidomycosis

Funding There was no funding for this manuscript.Peer reviewedPublisher PD

Monetary costs and hospital burden associated with the management of invasive fungal infections in Mexico: a multicenter study

Background: Invasive fungal infections (IFIs) affect >1.5 million people per year. Nevertheless, IFIs are usually neglected and underdiagnosed. IFIs should be considered as a public-health problem and major actions should be taken to tackle them and their associated costs. Aim To report the incidence of IFIs in four Mexican hospitals, to describe the economic cost associated with IFIs therapy and the impact of adverse events such as acute kidney injury (AKI), liver damage (LD), and ICU stay. Methods: This was a retrospective, transversal study carried-out in four Mexican hospitals. All IFIs occurring during 2016 were included. Incidence rates and estimation of antifungal therapy's expenditure for one year were calculated. Adjustments for costs of AKI were done. An analysis of factors associated with death, AKI, and LD was performed. Results: Two-hundred thirty-eight cases were included. Among all cases, AKI was diagnosed in 16%, LD in 25%, 35% required ICU stay, with a 23% overall mortality rate. AKI and LD showed higher mortality rates (39% vs 9% and 44% vs 18%, respectively, p < 0.0001). The overall incidence of IFIs was 4.8 cases (95% CI = 0.72–8.92) per 1000 discharges and 0.7 cases (95% CI = 0.03–1.16) per 1000 patients-days. Invasive candidiasis showed the highest incidence rate (1.93 per 1000 discharges, 95% CI = −1.01 to 2.84), followed by endemic IFIs (1.53 per 1000 discharges 95% CI = −3.36 to 6.4) and IA (1.25 per 1000 discharges, 95% CI = −0.90 to 3.45). AKI increased the cost of antifungal therapy 4.3-fold. The total expenditure in antifungal therapy for all IFIs, adjusting for AKI, was $233,435,536 USD (95$6,224,993 to $773,810,330). Conclusions: IFIs are as frequent as HIV asymptomatic infection and tuberculosis. Costs estimations allow to assess cost-avoidance strategies to increase targeted driven therapy and decrease adverse events and their costs

Neutralisation of SARS-CoV-2 by anatomical embalming solutions.

Teaching and learning anatomy by using human cadaveric specimens has been a foundation of medical and biomedical teaching for hundreds of years. Therefore, the majority of institutions that teach topographical anatomy rely on body donation programmes to provide specimens for both undergraduate and postgraduate teaching of gross anatomy. The COVID-19 pandemic has posed an unprecedented challenge to anatomy teaching because of the suspension of donor acceptance at most institutions. This was largely due to concerns about the potential transmissibility of the SARS-CoV-2 virus and the absence of data about the ability of embalming solutions to neutralise the virus. Twenty embalming solutions commonly used in institutions in the United Kingdom and Ireland were tested for their ability to neutralise SARS-CoV-2, using an established cytotoxicity assay. All embalming solutions tested neutralised SARS-CoV-2, with the majority of solutions being effective at high-working dilutions. These results suggest that successful embalming with the tested solutions can neutralise the SARS-CoV-2 virus, thereby facilitating the safe resumption of body donation programmes and cadaveric anatomy teaching

Surveillance of Candida spp Bloodstream Infections: Epidemiological Trends and Risk Factors of Death in Two Mexican Tertiary Care Hospitals

Introduction: Larger populations at risk, broader use of antibiotics and longer hospital stays have impacted on the incidence of Candida sp. bloodstream infections (CBSI).Objective: To determine clinical and epidemiologic characteristics of patients with CBSI in two tertiary care reference medical institutions in Mexico City.Design: Prospective and observational laboratory-based surveillance study conducted from 07/2008 to 06/2010.Methods: All patients with CBSI were included. Identification and antifungal susceptibility were performed using CLSI M27-A3 standard procedures. Frequencies, Mann-Whitney U test or T test were used as needed. Risk factors were determined with multivariable analysis and binary logistic regression analysis.Results: CBSI represented 3.8% of nosocomial bloodstream infections. Cumulative incidence was 2.8 per 1000 discharges (incidence rate: 0.38 per 1000 patient-days). C. albicans was the predominant species (46%), followed by C. tropicalis (26%). C. glabrata was isolated from patients with diabetes (50%), and elderly patients. Sixty-four patients (86%) received antifungals. Amphotericin-B deoxycholate (AmBD) was the most commonly used agent (66%). Overall mortality rate reached 46%, and risk factors for death were APACHE II score >= 16 (OR = 6.94, CI95% = 2.34-20.58, p<0.0001), and liver disease (OR = 186.11, CI95% = 7.61-4550.20, p = 0.001). Full susceptibility to fluconazole, AmBD and echinocandins among C. albicans, C. tropicalis, and C. parapsilosis was observed.Conclusions: the cumulative incidence rate in these centers was higher than other reports from tertiary care hospitals from Latin America. Knowledge of local epidemiologic patterns permits the design of more specific strategies for prevention and preemptive therapy of CBSI.Pfizer Inc.Salvador Zubiran Natl Inst Med Sci & Nutr, Dept Med, Mexico City, DF, MexicoHosp Escuela Tegucigalpa, Tegucigalpa, HondurasUniversidade Federal de São Paulo, Escola Paulista Med, Div Infect Dis, São Paulo, BrazilNatl Canc Inst, Div Infect Dis, Mexico City, DF, MexicoUniv Nacl Colombia, Dept Internal Med, Bogota, ColombiaUniv Peruana Cayetano Heredia, Dept Med, Lima, PeruHosp Vargas Caracas, Caracas, VenezuelaCtr Med Caracas, Caracas, VenezuelaUniv Fed Rio de Janeiro, Univ Hosp, Rio de Janeiro, BrazilUniv Texas Med Sch Houston, Mem Hermann Texas Med Ctr, Dept Med, Houston, TX USAUniv Fed Parana, Hosp Clin, BR-80060000 Curitiba, Parana, BrazilUniv Chile, Fac Med, Hosp Luis Calvo Mackenna, Dept Pediat, Santiago 7, ChileUniv Desarrollo, Clin Alemana, Dept Med, Santiago, ChileHosp Clin Jose San Martin, Infect Dis Unit, Buenos Aires, DF, ArgentinaPontificia Univ Catolica Ecuador, Fac Med, Hosp Vozandes, Quito, EcuadorUniversidade Federal de São Paulo, Escola Paulista Med, Div Infect Dis, São Paulo, BrazilPfizer Inc.: INF-168Web of Scienc